United States: On Friday, the US Food & Drug Administration (FDA) granted the Market approval to Syndax Pharmaceuticals drug known as Revumenib (branded Revuforj) for acute leukemia involving KMT2A translocation. This genetic mutation is seen in about 10% of acute ...